The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD

Cell Cycle

Volumn 8, Issue 11, 2009, Pages 1794-1802

  Li, Lequn ^a   Wang, Hui ^a   Jin, Sub Kim ^a   Pihan, German ^a   Boussiotis, Vassiliki A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Alloreactive T cells; Cdk inhibitors; Cell cycle; GvHD; NF B; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ROSCOVITINE; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; MOUSE; NONHUMAN; T LYMPHOCYTE;

EID: 66749113138     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.11.8738     Document Type: Article

References (37)

1. Abbas AK, Lohr J, Knoechel B. Balancing autoaggressive and protective T cell responses. J Autoimmun 2007; 28:59-61. (Pubitemid 46670685)
2. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003; 192:161-180 (Pubitemid 36613331)
3. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007; 25:171-192
4. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-2711 (Pubitemid 39507762)
5. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-231 (Pubitemid 38902433)
6. Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 2006; 7:1157-1165
7. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43:3-10. (Pubitemid 43063330)
8. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-536 (Pubitemid 27060443)
9. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444:949-952 (Pubitemid 46025010)
10. Park JY, Schutzer WE, Lindsley JN, Bagby SP, Oyama TT, Anderson S, et al. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol 2007; 8:12. (Pubitemid 350043324)
11. Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, et al. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum 2007; 56:1629-1637 (Pubitemid 46764092)
12. Pezzotta A, Mister M, Monteferrante G, Cassis L, Azzollini N, Aiello S, et al. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. Transplantation 2008; 85:1476-1482
13. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93:2738-2747 (Pubitemid 29181207)
14. 1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res 1998; 245:8-18.
15. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18:747-755 (Pubitemid 38500193)
16. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and downregulation of Mcl-1. Cancer Res 2005; 65:5399-5407 (Pubitemid 40827353)
17. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. Blood 2005; 106:1042-1047 (Pubitemid 41076452)
18. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16:1169-1176
19. Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007; 48:158-167 (Pubitemid 46978635)
20. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by downregulation of genes involved in transcription regulation and survival. Blood 2005; 105:4484-4491
21. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20:3206-3216 (Pubitemid 32553673)
22. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59.
23. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NFkappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 2008; 15:263-273
24. Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K, et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 1997; 158:5185-5190 (Pubitemid 127681221)
25. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70:272-279 (Pubitemid 30602742)
26. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101:2440-2445 (Pubitemid 36302094)
27. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112:1539-1542
28. Pahl HL. Activators and target genes of Rel/NFkappaB transcription factors. Oncogene 1999; 18:6853-6866
29. Zhong H, Voll RE, Ghosh S. Phosphorylation of NFkappaB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1:661-671 (Pubitemid 128379244)
30. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-562 (Pubitemid 20069191)
31. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12:1056-1064 (Pubitemid 44353387)
32. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:13.
33. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NFkappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006; 107:827-834 (Pubitemid 43076412)
34. Berthet C, Rodriguez-Galan MC, Hodge DL, Gooya J, Pascal V, Young HA, et al. Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2. Mol Cell Biol 2007; 27:5079-5089 (Pubitemid 47068283)
35. Song H, Vita M, Sallam H, Tehranchi R, Nilsson C, Siden A, et al. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro. Cancer Chemother Pharmacol 2007; 60:841-849 (Pubitemid 47389390)
36. Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A, Hassan M. Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res 2008; 58:32-37
37. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782-791 (Pubitemid 46192219)